Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?

European journal of medical research - 27 Sept 2023

Maslub Mohammed G, Radwan Mahasen A, Daud Nur Aizati Athirah, Sha'aban Abubakar

Abstract excerpt

INTRODUCTION: Atorvastatin is regarded as the most frequently prescribed statin worldwide for dyslipidemia. However, clinical response and risk of adverse effects to statin therapy are associated with genetic variations. Numerous research linked statins pharmacokinetics (PK) variations to genetic polymorphisms in cytochromes P450 (CYPs) metabolic enzymes. OBJECTIVE: This article reviews the association between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Pharmacogenetics and Drug Metabolism

Share to Polymorphism, Genetic

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 37759317
DOI: 10.1186/s40001-023-01038-1
PMCID: PMC10523700

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?PMID 37759317Read ↗

CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin.Semantic proximity Read ↗

Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.Semantic proximity Read ↗

Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping reviewSemantic proximity Read ↗

Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population.Semantic proximity Read ↗

Pharmacogenetics of statins treatment: Efficacy and safetySemantic proximity Read ↗

Comparative Analysis of Atorvastatin and Rosuvastatin Side Events and Risk Factors in the UAE Multiethnic Population: Focus on Pharmacogenomic VariantsSemantic proximity Read ↗

Impact of SLCO1B1 (rs2306283) polymorphism on personalized atorvastatin dosing in a genetically distinct South Asian cohort.Semantic proximity Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.Semantic proximity Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of StatinsSemantic proximity Read ↗

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.